絞り込み

18370

広告

S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development.

著者 Sobolewski C , Abegg D , Berthou F , Dolicka D , Calo N , Sempoux C , Fournier M , Maeder C , Ay AS , Clavien PA , Humar B , Dufour JF , Adibekian A , Foti M
Gut.2020 Jan 09 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (15view , 0users)
Hepatocellular carcinoma (HCC) development occurs with non-alcoholic fatty liver disease (NAFLD) in the absence of cirrhosis and with an increasing incidence due to the obesity pandemic. Mutations of tumour suppressor (TS) genes and oncogenes (ONC) have been widely characterised in HCC. However, mounting evidence indicates that non-genomic alterations of TS/ONC occur early with NAFLD, thereby potentially promoting hepatocarcinogenesis in an inflammatory/fibrotic context. The aim of this study was to identify and characterise these alterations.
PMID: 31919231 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード